Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melphalan SCHEMBL5872 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| (R)-Melphalan SCHEMBL5873 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL5325132 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL563239 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL41335 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL2723742 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL2680958 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL4150935 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL29061034 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL11029192 | 0.98 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 553 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2024238454-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-11-21 | — | — | WO | claimed |
| CN-116283627-A | Synthesis method of melphalan impurity G | 深圳市江川医药技术有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-20210032304-A1 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2021-02-04 | — | — | US | claimed |
| EP-3752174-A1 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | University of Florida Research Foundation, Incorporated (US) | 2020-12-23 | — | — | EP | claimed |
| EP-3071697-B1 | ADENOVIRUS EXPRESSING IMMUNE CELL STIMULATORY RECEPTOR AGONIST(S) | DNATRIX INC (US) | 2019-10-16 | — | — | EP | claimed |
| US-20190269744-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | CV BIOMANUFACTURING, LLC | 2019-09-05 | — | — | US | claimed |
| WO-2019160910-A1 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2019-08-22 | — | — | WO | claimed |
| EP-2806883-B1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | DNATRIX INC (US) | 2019-04-24 | — | — | EP | claimed |
| US-8921596-B2 | Process for the preparation of melphalan hydrochloride | Emcure Pharmaceuticals, Ltd. (IN) | 2014-12-30 | — | — | US | claimed |
| US-20120136335-A1 | FOCAL MEDICATION TITRATION SYSTEM | HOBBS JONATHAN P (US) | 2012-05-31 | — | — | US | claimed |
| US-20120116117-A1 | PROCESS FOR THE PREPARATION OF MELPHALAN HYDROCHLORIDE | EMCURE PHARMACEUTICALS LTD. (IN) | 2012-05-10 | — | — | US | claimed |
| US-20110077230-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | TATARSKIY, VALERIY (DE) | 2011-03-31 | — | — | US | claimed |
| CN-101584669-B | Melphalan freeze-dried powder injection | JIANGSU AOSAIKANG PHARM CO LTD | 2010-12-29 | — | — | CN | claimed |
| EP-2257558-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | Tatarskiy, Valeriy (DE) | 2010-12-08 | — | — | EP | claimed |
| EP-2130832-A1 | Copper organic complexes, use thereof as anti-tumour agent and protection of healthy tissue from ionised radiation | Tatarsky, Valeriy, Prof. Dr. (DE) | 2009-12-09 | — | — | EP | claimed |
| WO-2009103807-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2009-08-27 | — | — | WO | claimed |
| EP-0604301-B1 | p-Di[2-chloroethyl)amino]phenylalanine derivatives process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-05-29 | — | — | EP | claimed |
| EP-0604301-A1 | p-Di[2-chloroethyl)amino]phenylalanine derivatives process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-06-29 | — | — | EP | claimed |
| CN-122070936-A | Nanometer material based on supermolecule polypeptide-drug coupling prodrug, and preparation method and application thereof | 中国医学科学院生物医学工程研究所 | 2026-05-22 | — | — | CN | disclosed |
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3921420-B1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | OHIO STATE INNOVATION FOUNDATION (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4688003-A2 | LIPOSOMAL COMPOSITIONS OF ARCHEXIN | The Whiteoak Group, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260027276-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4630562-A1 | NUCLEIC ACID BASED CANCER VACCINE AND METHODS THEREOF | Advanced RNA Vaccine (ARV) Technologies, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250313835-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2025-10-09 | — | — | US | disclosed |
| EP-4626897-A1 | A NEW COPPER(II) COMPLEX CONTAINING 5-FLUOROURACIL AND TERPYRIDINE WITH ANTICANCER AND ANTIANGIOGENIC EFFECTS | Istinye Üniversitesi (TR) | 2025-10-08 | — | — | EP | disclosed |
| EP-4608812-A1 | VITAMIN-BASED LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME | Advanced RNA Vaccine (ARV) Technologies, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4603589-A2 | MICELLAR NANOPARTICLES AND USES THEREOF | Biorchestra Co., Ltd. (KR) | 2025-08-20 | — | — | EP | disclosed |
| EP-4594360-A1 | DESIGN AND UTILIZATION OF GENE TARGETING ANTIBODY FUSION PROTEINS TO PERFORM IN VIVO THERAPEUTIC GENE EDITING | Baylor College of Medicine (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12364797-B2 | Apparatus for removing chemotherapy compounds from blood | DELCATH SYSTEMS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025149946-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2025-07-17 | — | — | WO | disclosed |
| US-12357564-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | OHIO STATE INNOVATION FOUNDATION (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4577193-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | Ohio State Innovation Foundation (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025137555-A1 | POLYPEPTIDES THAT BIND TO NKP46 | OMNIAB, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4568645-A2 | STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME | Advanced RNA Vaccine (ARV) Technologies, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-3990028-B1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO LTD (KR) | 2025-06-04 | — | — | EP | disclosed |
| US-20250152781-A1 | TISSUE ENGINEERING AND DRUG DELIVERY DEVICE | OHIO STATE INNOVATION FOUNDATION | 2025-05-15 | — | — | US | disclosed |
| EP-4551193-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | Biorchestra Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119896746-A | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119896745-A | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2025076213-A1 | ISOTHERMALLY PHASE-SEPARABLE ELASTIN-LIKE POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025064985-A1 | Myc INHIBITOR PROTEINS AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092083-A1 | STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME | SUZHOU VENCUBIO LTD. (CN) | 2025-03-20 | — | — | US | disclosed |
| CN-113874046-B | Glycoside-containing peptide linkers for antibody-drug conjugates | R.P.谢勒技术有限责任公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4504750-A1 | METHODS AND COMPOSITIONS FOR TREATING GLIOMAS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250042963-A1 | METHODS FOR TREATING MYELOPROLIFERATIVE DISORDERS | ACCELERON PHARMA INC. (US) | 2025-02-06 | — | — | US | disclosed |
| CN-119136833-A | Membrane translocation domain and uses thereof | 俄亥俄州创新基金会 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024238454-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240358838-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2024-10-31 | — | — | US | disclosed |
| EP-4453029-A2 | POLYPEPTIDES TARGETING CD105+ CANCERS | Baylor College of Medicine (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240335585-A1 | TISSUE-ENGINEERED SCAFFOLDS AND METHODS OF MAKING | GEORGIA TECH RESEARCH CORPORATION | 2024-10-10 | — | — | US | disclosed |
| WO-2024206077-A2 | DOSING REGIMES AND COMBINATION THERAPIES USING ARCHEXIN FOR THE TREATMENT OF CANCER | THE WHITEOAK GROUP, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024206078-A2 | LIPOSOMAL COMPOSITIONS OF ARCHEXIN | THE WHITEOAK GROUP, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| CN-118726268-A | Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells | 诺华股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024186961-A1 | MITOCHONDRIA-TARGETED AGENTS FOR DISEASE PREVENTION AND TREATMENT | THE METHODIST HOSPITAL (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-4423116-A1 | METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA | Regents of the University of California (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4422651-A2 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING MAGE-A4 ANTIGEN AND METHODS OF USE | Board Of Regents, The University Of Texas System (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3386546-B1 | COMBINATION FOR THE EFFECTIVE TREATMENT OF METASTATIC CANCER IN PATIENTS | GENERAL ONCOLOGY INC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4413046-A2 | METHODS AND COMPOSITIONS COMPRISING B7-H3 BINDING POLYPEPTIDES | Board of Regents, The University of Texas System (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024162910-A1 | A NEW COPPER(II) COMPLEX CONTAINING 5-FLUOROURACIL AND TERPYRIDINE WITH ANTICANCER AND ANTIANGIOGENIC EFFECTS | ISTINYE UNIVERSITESI (TR) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024158700-A2 | METHODS AND COMPOSITIONS FOR TREATING EWING SARCOMA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-108473957-B | Methods for improving the efficacy and expansion of chimeric antigen receptor expressing cells | 诺华股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240216529-A1 | EXTRACELLULAR VESICLES WITH TARGETING MOIETY | BIORCHESTRA CO., LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240216308-A1 | Combination Therapy for Metastatic Cancer | GENERAL ONCOLOGY INC (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2024124232-A1 | NUCLEIC ACID BASED CANCER VACCINE AND METHODS THEREOF | ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240173348-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2024-05-30 | — | — | US | disclosed |
| EP-4373516-A1 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING FANCI, RAD51, AND PBK ANTIGENS AND METHODS OF USE | Board of Regents, The University of Texas System (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240156766-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024092209-A1 | VITAMIN-BASED LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME | ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240142403-A1 | Methods of Breath-Based Toxin Exposure Assessment, and Systems for Practicing the Same | DIAGNOSE EARLY, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024073528-A1 | DESIGN AND UTILIZATION OF GENE TARGETING ANTIBODY FUSION PROTEINS TO PERFORM IN VIVO THERAPEUTIC GENE EDITING | BAYLOR COLLEGE OF MEDICINE (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024064964-A2 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024044370-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4326291-A1 | METHODS AND COMPOSITIONS FOR GENETIC MODIFICATION AND THERAPEUTIC USE OF IMMUNE CELLS | Board of Regents, The University of Texas System (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024035710-A2 | STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME | ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4320145-A1 | METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES | Board of Regents, The University of Texas System (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11896668-B2 | Lyophilized preparation of cytotoxic dipeptides | ONCOPEPTIDES AB (SE) | 2024-02-13 | — | — | US | disclosed |
| EP-4314255-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER THERAPY-INDUCED NEUTROPENIC FEVER AND/OR GVHD | Board of Regents, The University of Texas System (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240024344-A1 | Methods For The Effective Treatment Of Metastatic Cancer | GENERAL ONCOLOGY, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2024009268-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| US-20230398063-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | OHIO STATE INNOVATION FOUNDATION | 2023-12-14 | — | — | US | disclosed |
| US-11839624-B2 | Micellar nanoparticles and uses thereof | BIORCHESTRA CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-20230382819-A1 | PROCESSES FOR SYNTHESIS OF ALPHA-EMITTING RADIOPHARMACEUTICALS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-11-30 | — | — | US | disclosed |
| EP-4271363-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | Biorchestra Co., Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023192626-A1 | METHODS AND COMPOSITIONS FOR TREATING GLIOMAS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| EP-4240378-A1 | ENGINEERED T CELL RECEPTORS TARGETING EGFR ANTIGENS AND METHODS OF USE | Board of Regents, The University of Texas System (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242176-A2 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | Delcath Systems, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11744842-B2 | Methods for the effective treatment of metastatic cancer | GENERAL ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230272120-A1 | IMMUNOMAGNETIC COMPOSITIONS FOR THE PH-SPECIFIC CAPTURE OF EXTRACELLULAR VESICLES | THE UNIVERSITY OF KANSAS | 2023-08-31 | — | — | US | disclosed |
| WO-2023164646-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-31 | — | — | WO | disclosed |
| CN-110831582-B | Pharmaceutical composition | 诺华股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4221726-A1 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | Baylor College of Medicine (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4218792-A1 | COMPOSITION FOR TREATING MYELOPROLIFERATIVE DISORDERS | Acceleron Pharma Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023133560-A2 | TISSUE ENGINEERING AND DRUG DELIVERY DEVICE | OHIO STATE INNOVATION FOUNDATION (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230211063-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2023122580-A2 | POLYPEPTIDES TARGETING CD105 + CANCERS | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-116327952-A | Methods for treating myeloproliferative disorders | 阿塞勒隆制药公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116283627-A | Synthesis method of melphalan impurity G | 深圳市江川医药技术有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116283627-A | Synthesis method of melphalan impurity G | 深圳市江川医药技术有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3590561-B1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-111417630-B | Modulators of interferon gene stimulating factor (STING) | 葛兰素史克知识产权开发有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-11660266-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2023076875-A1 | METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076863-A2 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING MAGE-A4 ANTIGEN AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11633528-B2 | Apparatus for removing chemotherapy compounds from blood | DELCATH SYSTEMS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2023060137-A2 | METHODS AND COMPOSITIONS COMPRISING B7-H3 BINDING POLYPEPTIDES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4161555-A1 | ENGINEERED T CELL RECEPTORS AND METHODS OF USE | Board of Regents, The University of Texas System (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4138889-A1 | METHODS FOR TREATING BLADDER CANCER | Board of Regents, The University of Texas System (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023001245-A1 | CONJUGATE OF CELL-PENETRATING PEPTIDE AND MELPHALAN, AND PREPARATION CONTAINING CONJUGATE | 奥朗生物医药有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023004289-A1 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING FANCI, RAD51, AND PBK ANTIGENS AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-4122482-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | Oncopeptides AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| CN-115554405-A | Medicine containing endonuclease inhibiting function and anti-tumor application thereof | 四川大学华西第二医院 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022271255-A1 | TISSUE-ENGINEERED SCAFFOLDS AND METHODS OF MAKING | GEORGIA TECH RESEARCH CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-115444842-A | Application of L-phenylalanine medicine | 云南农业大学 | 2022-12-09 | — | — | CN | disclosed |
| CN-111671904-B | Medicine containing endonuclease inhibiting function and anti-tumor application thereof | 四川大学华西第二医院 | 2022-12-06 | — | — | CN | disclosed |
| EP-3331550-B1 | COMPOSITION FOR TREATING MYELOPROLIFERATIVE DISORDERS | ACCELERON PHARMA INC (US) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022226101-A1 | METHODS AND COMPOSITIONS FOR GENETIC MODIFICATION AND THERAPEUTIC USE OF IMMUNE CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-4076669-A1 | METHODS FOR TREATING GLIOBLASTOMA | Board of Regents, The University of Texas System (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220332778-A1 | METHODS FOR TREATING MYELOPROLIFERATIVE DISORDERS | ACCELERON PHARMA INC. | 2022-10-20 | — | — | US | disclosed |
| US-20220323585-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2022-10-13 | — | — | US | disclosed |
| WO-2022216856-A1 | METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022204357-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER THERAPY-INDUCED NEUTROPENIC FEVER AND/OR GVHD | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-3656393-B1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2022-08-24 | — | — | EP | disclosed |
| US-20220257790-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO LTD (KR) | 2022-08-18 | — | — | US | disclosed |
| CN-108348578-B | Methods for treating myeloproliferative disorders | 阿塞勒隆制药公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022155311-A1 | METHODS AND SYSTEMS FOR ANALYSIS OF DRUG TARGET ENGAGEMENT AND TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022144811-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022140779-A2 | METHODS FOR DETECTING OR TREATING GLIOBLASTOMA MULTIFORME | BAYLOR RESEARCH INSTITUTE (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220205982-A1 | METHODS FOR DETERMINING PERSONALIZED FULL DOSE OF MELPHALAN IN REDUCED INTENSITY REGIMEN PRIOR TO HEMATOPOIETIC CELL TRANSPLANTATION | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-30 | — | — | US | disclosed |
| CN-114641292-A | Combination of bosutinib and VEGFR2 inhibitor and use thereof | 光谱制药有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022122668-A1 | COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-06-16 | — | — | WO | disclosed |
| CN-114630841-A | Antibodies and blocking the interaction of VISTA and its binding partner | 真和制药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-4008330-A1 | COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-06-08 | — | — | EP | disclosed |
| US-11344622-B2 | Lyophilized preparation of cytotoxic dipeptides | ONCOPEPTIDES AB (SE) | 2022-05-31 | — | — | US | disclosed |
| CN-114514038-A | Micellar nanoparticles and uses thereof | 生物欧赛加有限责任公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2022098850-A1 | ENGINEERED T CELL RECEPTORS TARGETING EGFR ANTIGENS AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3990028-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | Biorchestra Co., Ltd. (KR) | 2022-05-04 | — | — | EP | disclosed |
| US-20220118159-A1 | ANTIOXIDANT-RELEASING VITREOUS SUBSTITUTES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| US-20220117888-A1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| WO-2022081791-A1 | PROCESSES FOR SYNTHESIS OF ALPHA-EMITTING RADIOPHARMACEUTICALS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022076403-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220111132-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| CN-114315618-A | Preparation method of synthetic melphalan | 浙江恒腾福生物科技集团有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220105123-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2022-04-07 | — | — | US | disclosed |
| WO-2022072990-A1 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | BAYLOR COLLEGE OF MEDICINE (US) | 2022-04-07 | — | — | WO | disclosed |
| CN-114269715-A | Dibenzylamines as amino acid transport inhibitors | 范德比尔特大学 | 2022-04-01 | — | — | CN | disclosed |
| US-20220096405-A1 | Combination Therapy for Metastatic Cancer | GENERAL ONCOLOGY, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3969905-A1 | METHODS FOR DETERMINING PERSONALIZED FULL DOSE OF MELPHALAN IN REDUCED INTENSITY REGIMEN PRIOR TO HEMATOPOIETIC CELL TRANSPLANTATION | Children's Hospital Medical Center (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114222729-A | Amino acid transport inhibitors and uses thereof | 范德比尔特大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-114206355-A | Methods and compositions for treating cancer with cancer-targeting adjuvants | 芝加哥大学 | 2022-03-18 | — | — | CN | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11241522-B2 | Apparatus for removing chemotherapy compounds from blood | DELCATH SYSTEMS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| CN-113979964-A | Preparation and application of phenylalanine derivatives containing 1,3, 4-oxadiazole thioether | 贵州大学 | 2022-01-28 | — | — | CN | disclosed |
| WO-2021130163-A1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | INDENA S.P.A. (IT) | 2021-07-01 | — | — | WO | disclosed |
| US-20210155903-A1 | Combination Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-05-27 | — | — | US | disclosed |
| WO-2021080955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021080950-A1 | METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10940128-B2 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2021-03-09 | — | — | US | disclosed |
| US-20210032304-A1 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2021-02-04 | — | — | US | disclosed |
| EP-3752174-A1 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | University of Florida Research Foundation, Incorporated (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10869928-B2 | Lyophilized preparation of cytotoxic dipeptides | ONCOPEPTIDES AB (SE) | 2020-12-22 | — | — | US | disclosed |
| US-20200345848-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2020-11-05 | — | — | US | disclosed |
| EP-3721878-A1 | METHODS FOR THE EFFECTIVE TREATMENT OF METASTATIC CANCER | Glazier, Arnold (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3702783-A1 | METHODS FOR DETERMINING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | Analiza, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3280721-B1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| EP-3228319-B1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3656393-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | Oncopeptides AB (SE) | 2020-05-27 | — | — | EP | disclosed |
| US-20200147288-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200121794-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2020-04-23 | — | — | US | disclosed |
| US-10569004-B2 | Apparatus for removing chemotherapy compounds from blood | DELCATH SYSTEMS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10543274-B2 | Lyophilized preparation of cytotoxic dipeptides | ONCOPEPTIDES AB (SE) | 2020-01-28 | — | — | US | disclosed |
| EP-2434886-B1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190290823-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| CN-110225983-A | Methods of treating cancer | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-09-10 | — | — | CN | disclosed |
| WO-2019160910-A1 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2019-08-22 | — | — | WO | disclosed |
| CN-106061481-B | The combination of androgen receptor inhibitor and AKT inhibitor for treating cancer | 诺华股份有限公司 | 2019-08-16 | — | — | CN | disclosed |
| US-20190240332-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2019-08-08 | — | — | US | disclosed |
| US-20190240240-A1 | Methods For The Effective Treatment Of Metastatic Cancer | GENERAL ONCOLOGY, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10369264-B2 | Apparatus for removing chemotherapy compounds from blood | DELCATH SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3241576-B1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS INC (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10358454-B2 | Marinopyrrole derivatives and methods of making and using same | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10322182-B2 | Lyophilized preparation of cytotoxic dipeptides | ONCOPEPTIDES AB (SE) | 2019-06-18 | — | — | US | disclosed |
| CN-109806266-A | Combination and its application use for cancer treatment | 诺华股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| US-10293056-B1 | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-21 | — | — | US | disclosed |
| CN-109789135-A | ISOQUINOLINE DERIVATIVES AS PERK INHIBITORS | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | ONCOPEPTIDES AB (SE) | 2019-05-14 | — | — | US | disclosed |
| EP-2970102-B1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF MELPHALAN AND THE HYDROCHLORIDE SALT | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2019-05-08 | — | — | EP | disclosed |
| CN-109674801-A | Combination | 诺华股份有限公司 | 2019-04-26 | — | — | CN | disclosed |
| CN-106459131-B | Cyclic annular dinucleotides as STING regulator | 葛兰素史克知识产权开发有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-109608443-A | Heterocycleamide as protein modulator | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-109563081-A | It can be used as the heterocycleamide class of protein modulators | 葛兰素史克知识产权开发有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20190001044-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2776086-B1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| CN-109071514-A | Heterocyclic amides as protein modulators | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108884161-A | Combination therapy and uses and methods thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-3388060-A1 | METHODS FOR THE EFFECTIVE TREATMENT OF METASTATIC CANCER | Glazier, Arnold (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10098997-B2 | Apparatus for removing chemotherapy compounds from blood | DELCATH SYSTEMS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180265522-A1 | MARINOPYRROLE DERIVATIVES AND METHODS OF MAKING AND USING SAME | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-09-20 | — | — | US | disclosed |
| US-20180237377-A1 | Process for the Synthesis of Melphalan and the Hydrochloride Salt | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2018-08-23 | — | — | US | disclosed |
| CN-108290947-A | Combination therapy and uses and methods thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-108218731-A | The preparation method of melphalan dimer hydrochloride and application | 江苏先声药业有限公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-108136024-A | TLR4 agonists and combinations thereof and their purposes in treating cancer | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2018-05-31 | — | — | US | disclosed |
| US-9963422-B2 | Process for the synthesis of melphalan and the hydrochloride salt | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2018-05-08 | — | — | US | disclosed |
| US-20180071328-A1 | Methods for the Effective Treatment of Metastatic Cancer | GENERAL ONCOLOGY, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| EP-3280721-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | Oncopeptides AB (SE) | 2018-02-14 | — | — | EP | disclosed |
| EP-2405916-B1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH INC (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-2405916-B1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20180028740-A1 | Apparatus for Removing Chemotherapy Compounds from Blood | DELCATH SYSTEMS, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9868747-B2 | Marinopyrrole derivatives and methods of making and using same | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| EP-3241576-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | Delcath Systems, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3228319-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | Oncopeptides AB (SE) | 2017-10-11 | — | — | EP | disclosed |
| US-20170226047-A1 | PROCESS FOR THE PURIFICATION OF MELPHALAN | FARMABIOS SPA (IT) | 2017-08-10 | — | — | US | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9707331-B2 | Apparatus for removing chemotherapy compounds from blood | DELCATH SYSTEMS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2701720-B1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9663450-B2 | Process for the purification of melphalan | FARMABIOS S.P.A. (IT) | 2017-05-30 | — | — | US | disclosed |
| US-9655975-B2 | Prodrug using nitroimidazole | UNIVERSITY OF TSUKUBA (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9655975-B2 | Prodrug using nitroimidazole | UNIVERSITY OF TSUKUBA (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20170137431-A1 | MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-05-18 | — | — | US | disclosed |
| US-20170050981-A1 | MARINOPYRROLE DERIVATIVES AND METHODS OF MAKING AND USING SAME | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170049894-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2017-02-23 | — | — | US | disclosed |
| CN-106389307-A | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | 锡德克斯药物公司 | 2017-02-15 | — | — | CN | disclosed |
| US-9566351-B2 | Molecular containers and methods of making and using same | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2016180740-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2016-11-17 | — | — | WO | disclosed |
| US-9340501-B2 | Marinopyrrole derivatives as anticancer agents | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9335320-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9335320-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9335320-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160090352-A1 | PROCESS FOR THE PURIFICATION OF MELPHALAN | FARMABIOS S.P.A (IT) | 2016-03-31 | — | — | US | disclosed |
| CN-102625807-B | 4-Substituted pyridin-3-yl-carboxamide compounds and methods of use | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-09 | — | — | CN | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20160038651-A1 | COMPOUNDS AND COMPOSITIONS FOR DRUG RELEASE | RIPPLE THERAPEUTICS CORPORATION (CA) | 2016-02-11 | — | — | US | disclosed |
| US-20160038651-A1 | COMPOUNDS AND COMPOSITIONS FOR DRUG RELEASE | RIPPLE THERAPEUTICS CORPORATION (CA) | 2016-02-11 | — | — | US | disclosed |
| US-20160016889-A1 | An Improved Process for the Synthesis of Melphalan and the Hydrochloride Salt | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2016-01-21 | — | — | US | disclosed |
| EP-2970102-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF MELPHALAN AND THE HYDROCHLORIDE SALT | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2016-01-20 | — | — | EP | disclosed |
| US-20150335768-A1 | ErbB-2 RECEPTOR TARGETING PEPTIDE | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2939695-A1 | POLYMERIC COUPLING AGENTS AND PHARMACEUTICALLY-ACTIVE POLYMERS MADE THEREFROM | Interface Biologics Inc. (CA) | 2015-11-04 | — | — | EP | disclosed |
| EP-2475659-B1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20150265641-A1 | Methods for the Effective Treatment of Metastatic Cancer | GENERAL ONCOLOGY, INC. | 2015-09-24 | — | — | US | disclosed |
| WO-2015126912-A1 | MARINOPYRROLE DERIVATIVES AND METHODS OF MAKING AND USING SAME | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| EP-2908809-A2 | METHODS FOR THE EFFECTIVE TREATMENT OF METASTATIC CANCER | Glazier, Arnold (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-1786449-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGEN IN COMBINATION WITH A CYTOSTATIC AGENT | ACTIVE BIOTECH AB (SE) | 2015-07-01 | — | — | EP | disclosed |
| US-9061054-B2 | ErbB-2 receptor targeting peptide | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-06-23 | — | — | US | disclosed |
| US-9012838-B2 | Covalently functionalized nanodiamond-based MALDI matrices and methods of use thereof | UNIVERSITY OF SASKATCHEWAN (CA) | 2015-04-21 | — | — | US | disclosed |
| US-9012838-B2 | Covalently functionalized nanodiamond-based MALDI matrices and methods of use thereof | UNIVERSITY OF SASKATCHEWAN (CA) | 2015-04-21 | — | — | US | disclosed |
| US-20150080632-A1 | MARINOPYRROLE DERIVATIVES AS ANTICANCER AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-19 | — | — | US | disclosed |
| US-8921596-B2 | Process for the preparation of melphalan hydrochloride | Emcure Pharmaceuticals, Ltd. (IN) | 2014-12-30 | — | — | US | disclosed |
| US-20140378673-A1 | PRODRUG USING NITROIMIDAZOLE | UNIVERSITY OF TSUKUBA (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378673-A1 | PRODRUG USING NITROIMIDAZOLE | UNIVERSITY OF TSUKUBA (JP) | 2014-12-25 | — | — | US | disclosed |
| WO-2014191426-A1 | PROCESS FOR THE PURIFICATION OF MELPHALAN | FARMABIOS S.P.A. (IT) | 2014-12-04 | — | — | WO | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| US-20140312218-A1 | COVALENTLY FUNCTIONALIZED NANODIAMOND-BASED MALDI MATRICES AND METHODS OF USE THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140312218-A1 | COVALENTLY FUNCTIONALIZED NANODIAMOND-BASED MALDI MATRICES AND METHODS OF USE THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-10-02 | — | — | US | disclosed |
| WO-2014141294-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF MELPHALAN AND THE HYDROCHLORIDE SALT | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139033-A1 | COMPOUNDS AND COMPOSITIONS FOR DRUG RELEASE | INTERFACE BIOLOGICS, INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| EP-2776086-A2 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | Delcath Systems, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8834938-B2 | Use of arsenic for cancer therapy protection | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140221488-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8795738-B2 | Use of arsenic for cancer therapy protection | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-08-05 | — | — | US | disclosed |
| CN-103826645-A | Use of arsenic for cancer therapy protection | UNIV TEXAS | 2014-05-28 | — | — | CN | disclosed |
| US-20140128462-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2014-05-08 | — | — | US | disclosed |
| WO-2014066400-A2 | METHODS FOR THE EFFECTIVE TREATMENT OF METASTATIC CANCER | GLAZIER ARNOLD (US) | 2014-05-01 | — | — | WO | disclosed |
| EP-2711000-A1 | Targeted Liposomes | Georgetown University (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2707008-A1 | USE OF ARSENIC FOR CANCER THERAPY PROTECTION | Board of Regents, The University of Texas System (US) | 2014-03-19 | — | — | EP | disclosed |
| CN-102030671-B | Preparing method of pharmaceutical melphalam, and hydrochloride and dihydrochloride of pharmaceutical melphalam | ZHEJIANG CHEMPACIFIC CHEMICAL CO LTD | 2014-02-19 | — | — | CN | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130330765-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8575385-B2 | Process of making optically pure melphalan | NAVINTA LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130289223-A1 | POLYMERIC COUPLING AGENTS AND PHARMACEUTICALLY-ACTIVE POLYMERS MADE THEREFROM | INTERFACE BIOLOGICS INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-20130289223-A1 | POLYMERIC COUPLING AGENTS AND PHARMACEUTICALLY-ACTIVE POLYMERS MADE THEREFROM | INTERFACE BIOLOGICS INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| WO-2013158197-A1 | MARINOPYRROLE DERIVATIVES AS ANTICANCER AGENTS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| EP-2268827-B1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | NAVINTA LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| US-8536161-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536161-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536161-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8530434-B2 | Nitroxide free radical synergized antineoplastic agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530434-B2 | Nitroxide free radical synergized antineoplastic agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| WO-2013070809-A2 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130116658-A1 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD | DELCATH SYSTEMS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8435976-B2 | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8431735-B2 | Processes for preparing pharmaceutical grade melphalans from industrial grade reactants | CHEMPACIFIC CORPORATION (US) | 2013-04-30 | — | — | US | disclosed |
| EP-1718667-B1 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-8349309-B2 | Polymeric coupling agents and pharmaceutically-active polymers made therefrom | INTERFACE BIOLOGICS INC. (CA) | 2013-01-08 | — | — | US | disclosed |
| US-8349309-B2 | Polymeric coupling agents and pharmaceutically-active polymers made therefrom | INTERFACE BIOLOGICS INC. (CA) | 2013-01-08 | — | — | US | disclosed |
| US-8334306-B2 | Nitroxide free radical synergized antineoplastic agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334306-B2 | Nitroxide free radical synergized antineoplastic agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120294955-A1 | USE OF ARSENIC FOR CANCER THERAPY PROTECTION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-11-22 | — | — | US | disclosed |
| WO-2012155061-A1 | USE OF ARSENIC FOR CANCER THERAPY PROTECTION | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-15 | — | — | WO | disclosed |
| US-8293243-B2 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent | ACTIVE BIOTECH AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-8278098-B2 | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins | VEGENICS PTY LIMITED (AU) | 2012-10-02 | — | — | US | disclosed |
| CN-102625807-A | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | HOFFMANN LA ROCHE | 2012-08-01 | — | — | CN | disclosed |
| US-20120190887-A1 | Processes for preparing pharmaceutical grade melphalans from industrial grade reactants | CHEMPACIFIC CORPORATION | 2012-07-26 | — | — | US | disclosed |
| EP-2475659-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120136335-A1 | FOCAL MEDICATION TITRATION SYSTEM | HOBBS JONATHAN P (US) | 2012-05-31 | — | — | US | disclosed |
| CN-102038652-B | Melphalan multi-targeting drug delivery system and preparation method and application thereof | UNIV WUHAN TECH | 2012-05-30 | — | — | CN | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| CN-102458114-A | Injectable melphalan compositions containing cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS INC | 2012-05-16 | — | — | CN | disclosed |
| US-20120116117-A1 | PROCESS FOR THE PREPARATION OF MELPHALAN HYDROCHLORIDE | EMCURE PHARMACEUTICALS LTD. (IN) | 2012-05-10 | — | — | US | disclosed |
| US-20120065230-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065230-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120029021-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120029021-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2405916-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | Genentech, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-1390075-B1 | CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY IN GENE THERAPY | UNIV CHICAGO (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110250291-A1 | USE OF ARSENIC FOR CANCER THERAPY PROTECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-13 | — | — | US | disclosed |
| US-20110207664-A1 | Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins | VEGENICS PTY LIMITED (AU) | 2011-08-25 | — | — | US | disclosed |
| US-7989434-B2 | Heterocyclic self-immolative linkers and conjugates | SEATTLE GENETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2011078782-A1 | A COMPOSITION COMPRISING OF MELPHALAN DERIVATIVES AND GEMCITABINE OR ETOPOSIDE USEFUL IN THE TREATMENT OF CANCER | ONCOPEPTIDES AB (SE) | 2011-06-30 | — | — | WO | disclosed |
| US-20110117008-A1 | USE OF AVICINS TO DELIVER THERAPEUTIC AND DIAGNOSTIC AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110112259-A1 | POLYMERIC COUPLING AGENTS AND PHARMACEUTICALLY-ACTIVE POLYMERS MADE THEREFROM | INTERFACE BIOLOGICS, INC (CA) | 2011-05-12 | — | — | US | disclosed |
| US-20110112259-A1 | POLYMERIC COUPLING AGENTS AND PHARMACEUTICALLY-ACTIVE POLYMERS MADE THEREFROM | INTERFACE BIOLOGICS, INC (CA) | 2011-05-12 | — | — | US | disclosed |
| CN-102038652-A | Melphalan multi-targeted drug carrying system, and preparation method and application thereof | UNIV WUHAN SCIENCE & ENG | 2011-05-04 | — | — | CN | disclosed |
| CN-102030671-A | Preparing method of pharmaceutical melphalam, and hydrochloride and dihydrochloride of pharmaceutical melphalam | ZHEJIANG CHEMPACIFIC CHEMICAL CO LTD | 2011-04-27 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| CN-102007134-A | Organic copper complexes and their use as anti-cancer agents and for protecting normal tissues from ionizing radiation | CHARITE UNIVERSITATSMEDIZIN BE | 2011-04-06 | — | — | CN | disclosed |
| US-20110077230-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | TATARSKIY, VALERIY (DE) | 2011-03-31 | — | — | US | disclosed |
| US-7910607-B2 | Nitroxide free radical synergized antineoplastic agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910607-B2 | Nitroxide free radical synergized antineoplastic agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2011-03-22 | — | — | US | disclosed |
| WO-2011029802-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7902149-B2 | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins | VEGENICS PTY LIMITED (AU) | 2011-03-08 | — | — | US | disclosed |
| EP-2268827-A1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | Navinta, llc. (US) | 2011-01-05 | — | — | EP | disclosed |
| CN-101584669-B | Melphalan freeze-dried powder injection | JIANGSU AOSAIKANG PHARM CO LTD | 2010-12-29 | — | — | CN | disclosed |
| US-7858592-B2 | Interfering RNAs against the promoter region of P53 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100311838-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| EP-2257558-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | Tatarskiy, Valeriy (DE) | 2010-12-08 | — | — | EP | disclosed |
| EP-2257558-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | Tatarskiy, Valeriy (DE) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010138141-A1 | COMBINATION THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA | CEPHALON, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138101-A1 | COMBINATION THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA USING CEP-18770 TOGETHER WITH BORTEZOMIB OR MEPHALAN | CEPHALON, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138920-A1 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100303836-A1 | TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN COMBINATION WITH ANOTHER ANTICANCER AGENT | HEDLUND GUNNAR | 2010-12-02 | — | — | US | disclosed |
| US-20100273843-A1 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | SEAGEN INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2009103807-A8 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010105008-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010105008-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7795305-B2 | CDDO-compounds and combination therapies thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-09-14 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2222339-A2 | USE OF AVICINS TO DELIVER THERAPEUTIC AND DIAGNOSTIC AGENTS | Research Development Foundation (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7771723-B2 | Remedies for myeloma to be used together with nitrogen mustard antitumor agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7763253-B2 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent | ACTIVE BIOTECH, AB (SE) | 2010-07-27 | — | — | US | disclosed |
| US-7754681-B2 | Heterocyclic self-immolative linkers and conjugates | SEATTLE GENETICS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7723036-B2 | Assessing response to anti-CD20 therapy by genotyping C1q components | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20100061930-A1 | ErbB-2 RECEPTOR TARGETING PEPTIDE | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2010-03-11 | — | — | US | disclosed |
| EP-1290011-B1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | ONCOPEPTIDES AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-7662360-B2 | boron neutron capture therapy | PSIMEI PHARMACEUTICALS PLC (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7662360-B2 | boron neutron capture therapy | PSIMEI PHARMACEUTICALS PLC (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20090318352-A1 | Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins | VEGENICS LIMITED (AU) | 2009-12-24 | — | — | US | disclosed |
| EP-2130832-A1 | Copper organic complexes, use thereof as anti-tumour agent and protection of healthy tissue from ionised radiation | Tatarsky, Valeriy, Prof. Dr. (DE) | 2009-12-09 | — | — | EP | disclosed |
| EP-2130832-A1 | Copper organic complexes, use thereof as anti-tumour agent and protection of healthy tissue from ionised radiation | Tatarsky, Valeriy, Prof. Dr. (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009143468-A1 | TUMOR SUPPRESSOR-BASED SUSCEPTIBILITY OF HYPERPROLIFERATIVE CELLS TO ONCOLYTIC VIRAL THERAPY | UTI LIMITED PARTNERSHIP (CA) | 2009-11-26 | — | — | WO | disclosed |
| CN-101584669-A | Melphalan freeze-dried powder injection | JIANGSU AOSAIKANG PHARMACEUTIC (CN) | 2009-11-25 | — | — | CN | disclosed |
| US-7611711-B2 | VEGFR-3 inhibitor materials and methods | VEGENICS LIMITED (AU) | 2009-11-03 | — | — | US | disclosed |
| WO-2009102375-A9 | USE OF AVICINS TO DELIVER THERAPEUTIC AND DIAGNOSTIC AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009117164-A1 | PROCESS OF MAKING OPTICALLY PURE MELPHALAN | NAVINTA LLC (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090240074-A1 | Process Of Making Optically Pure Melphalan | PROVIDENT BANK | 2009-09-24 | — | — | US | disclosed |
| US-7585509-B2 | Tyrosine kinase type 1 family of receptors; cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2009-09-08 | — | — | US | disclosed |
| WO-2009103807-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103807-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009102375-A2 | USE OF AVICINS TO DELIVER THERAPEUTIC AND DIAGNOSTIC AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2009-08-20 | — | — | WO | disclosed |
| US-7566453-B2 | Methods for treating melanomas | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-07-28 | — | — | US | disclosed |
| US-7566566-B2 | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins | Vengenics Limited (AU) | 2009-07-28 | — | — | US | disclosed |
| US-20090099109-A1 | INTERFERING RNAS AGAINST THE PROMOTER REGION OF P53 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| US-20090093447-A1 | CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE | 2009-04-09 | — | — | US | disclosed |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | SEAGEN INC. | 2009-02-12 | — | — | US | disclosed |
| US-20090004145-A1 | COMPOSITIONS AND METHODS INVOLVING GENE THERAPY AND PROTEASOME MODULATION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-01 | — | — | US | disclosed |
| US-20080317723-A1 | LYMPHATIC ENDOTHELIAL CELLS MATERIALS AND METHODS | VEGENICS LIMITED (AU) | 2008-12-25 | — | — | US | disclosed |
| US-20080318907-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318907-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | THE TRUSTEES OF CALIFORNIA STATE UNIVERSITY (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080293652-A1 | Combination of Ad-P53 and Chemotherapy for the Treatment of Tumours | INTROGEN THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1989329-A2 | DETECTION AND DIAGNOSIS OF SMOKING RELATED CANCERS | Board of Regents, The University of Texas System (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7435755-B2 | Inducing cytotoxicity in a cell comprising contacting with a CDDO-compound and a chemotherapeutic agent | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008070858-A1 | INHIBITING TRANSLATION OF ABRERRANT DNMT3B TRANSCRIPTS IN CANCER CELLS USING INHIBITORY NUCLEIC ACIDS | UNIVERSITY OF CHICAGO (US) | 2008-06-12 | — | — | WO | disclosed |
| US-7375078-B2 | Heterocyclic self-immolative linkers and conjugates | GENENTECH, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-20080058263-A1 | Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-06 | — | — | US | disclosed |
| US-7309604-B2 | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins | LICENTIA, LTD. (FI) | 2007-12-18 | — | — | US | disclosed |
| US-20070258891-A1 | Conjugates of N-Hydroxypropymethacrylamide-Methacrylate Copolymer with Nuclide Activation Agent and/or Anti-Cancer Compounds | PSIMEI PHARMACEUTICALS PLC (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070258891-A1 | Conjugates of N-Hydroxypropymethacrylamide-Methacrylate Copolymer with Nuclide Activation Agent and/or Anti-Cancer Compounds | PSIMEI PHARMACEUTICALS PLC (GB) | 2007-11-08 | — | — | US | disclosed |
| EP-1259626-B1 | MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAS AND PROTEINS AND SCREENING METHODS FOR MODULATORS | LUDWIG INST CANCER RES (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1355566-A4 | LOCAL REGIONAL CHEMOTHERAPY AND RADIOTHERAPY USING IN SITU HYDROGEL | UNIV TEXAS (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070244076-A1 | Site and Rate Selective Prodrug Formulations of D609 with Antioxidant and Anticancer Activity | MUSC FOUNDATION RESEARCH DEVELOPMENT (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070231304-A1 | PROGNOSTIC FACTORS FOR ANTI-HYPERPROLIFERATIVE DISEASE GENE THERAPY | INTROGEN THERAPEUTICS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070218480-A1 | DETECTION AND DIAGNOSIS OF SMOKING RELATED CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-09-20 | — | — | US | disclosed |
| EP-1395255-A4 | CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF | UNIV TEXAS (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007092944-A2 | COMPOSITIONS AND METHODS INVOLVING GENE THERAPY AND PROTEASOME MODULATION | INTROGEN THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070191262-A1 | Cancer Therapy and Prevention Based on Modulation of Complement activity | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007090125-A2 | PROGNOSTIC FACTORS FOR ANTI-HYPERPROLIFERATIVE DISEASE GENE THERAPY | INTROGEN THERAPEUTICS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007087612-A2 | DETECTION AND DIAGNOSIS OF SMOKING RELATED CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070167353-A1 | PRODRUG COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-07-19 | — | — | US | disclosed |
| US-20070167353-A1 | PRODRUG COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2007-07-19 | — | — | US | disclosed |
| US-20070128626-A1 | Assessing response to anti-CD20 therapy by genotyping C1q components | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2007-06-07 | — | — | US | disclosed |
| EP-1786449-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN COMBINATION WITH ANOTHER ANTICANCER AGENT | Active Biotech AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1758615-A2 | COMBINATION TREATMENT OF CANCER WITH ELICITOR OF GENE PRODUCT EXPRESSION AND GENE-PRODUCT TARGETING AGENT | Board of Regents, The University of Texas System (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2007022374-A2 | ASSESSING RESPONSE TO ANTI-CD20 THERAPY BY GENOTYPING C1Q COMPONENTS | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1754488-A1 | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases | Introgen Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060269548-A1 | Lymphatic endothelial cells materials and methods | LICENTIA LTD. (FI) | 2006-11-30 | — | — | US | disclosed |
| US-7122353-B2 | Targeted carrier fusions for delivery of chemotherapeutic agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1180016-B1 | METHODS AND COMPOSITIONS FOR NON-VIRAL GENE THERAPY FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | INTROGEN THERAPEUTICS INC (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20060188437-A1 | Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM | 2006-08-24 | — | — | US | disclosed |
| US-20060115834-A1 | Methods of identifying metastatic potential in cancer | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2006-06-01 | — | — | US | disclosed |
| EP-1651766-A2 | TARGETED CARRIER FUSIONS FOR DELIVERY OF CHEMOTHERAPEUTIC AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006044439-A2 | METHODS OF IDENTIFYING METASTATIC POTENTIAL IN CANCER | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1425580-A4 | LYMPHATIC ENDOTHELIAL CELLS MATERIALS AND METHODS | LUDWIG INST CANCER RES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060057111-A1 | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent | ACTIVE BIOTECH (CH) | 2006-03-16 | — | — | US | disclosed |
| US-20060052322-A1 | Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent | INTROGEN THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
| US-7008633-B2 | Local regional chemotherapy and radiotherapy using in situ hydrogel | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-03-07 | — | — | US | disclosed |
| US-7005424-B2 | Nucleic acid encoding an E1A gene product sensitizes HER-2/neu overexpressing cancer cells to chemotherapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-02-28 | — | — | US | disclosed |
| WO-2006015882-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN COMBINATION WITH ANOTHER ANTICANCER AGENT | ACTIVE BIOTECH AB (SE) | 2006-02-16 | — | — | WO | disclosed |
| US-6992207-B2 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | ONCOPEPTIDES AB (SE) | 2006-01-31 | — | — | US | disclosed |
| WO-2005123141-A2 | COMBINATION TREATMENT OF CANCER WITH ELICITOR OF GENE PRODUCT EXPRESSION AND GENE-PRODUCT TARGETING AGENT | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005120588-A2 | PEPTIDES DELIVERED TO CELL NUCLEI | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050267024-A1 | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2005-12-01 | — | — | US | disclosed |
| US-6965010-B2 | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins | LICENTIA, LTD. (FI) | 2005-11-15 | — | — | US | disclosed |
| US-20050227910-A1 | LOCAL REGIONAL CHEMOTHERAPY AND RADIOTHERAPY USING IN SITU HYDROGEL | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-10-13 | — | — | US | disclosed |
| US-20050220706-A1 | Erbb-2 receptor targeting peptide | US GOVERNMENT - SECRETARY OF THE ARMY | 2005-10-06 | — | — | US | disclosed |
| US-20050208138-A1 | Local regional chemotherapy and radiotherapy using in situ hydrogel | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-09-22 | — | — | US | disclosed |
| WO-2005082422-A1 | COMBINATION OF AD-P53 AND CHEMOTHERAPY FOR THE TREATMENT OF TUMOURS | INTROGEN THERAPEUTICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-6919425-B2 | Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2005032492-A2 | SITE AND RATE SELECTIVE PRODRUG FORMULATIONS OF D609 WITH ANTIOXIDANT AND ANTICANCER ACTIVITY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050059122-A1 | Targeted carrier fusions for delivery of chemotherapeutic agents | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-03-17 | — | — | US | disclosed |
| WO-2005014823-A2 | TARGETED CARRIER FUSIONS FOR DELIVERY OF CHEMOTHERAPEUTIC AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-02-17 | — | — | WO | disclosed |
| US-6846809-B2 | PEI: DNA vector formulations for in vitro and in vivo gene delivery | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040266834-A1 | Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy | COPLAND JOHN A (US) | 2004-12-30 | — | — | US | disclosed |
| CN-1555488-A | Lymphatic endothelial cell material and methods | 路德维格癌症研究院 | 2004-12-15 | — | — | CN | disclosed |
| US-20040242523-A1 | Chemo-inducible cancer gene therapy | ANA-FARBER CANCER INSTITUE AND THE UNIVIERSITY OF CHICAGO | 2004-12-02 | — | — | US | disclosed |
| US-20040180371-A1 | Methods and compositions of a novel serine protease inhibitor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-09-16 | — | — | US | disclosed |
| EP-1425580-A2 | LYMPHATIC ENDOTHELIAL CELLS MATERIALS AND METHODS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20040097421-A1 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | ONCOPEPTIDES INNOVATION AB (SE) | 2004-05-20 | — | — | US | disclosed |
| EP-1409520-A2 | VEGFR-3 INHIBITOR MATERIALS AND METHODS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20040072755-A1 | TF antagonist | STENNICKE HENNING RALF (DK) | 2004-04-15 | — | — | US | disclosed |
| WO-2002057299-A9 | VEGFR-3 BINDING PEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS | LUDWIG INST CANCER RES (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040053863-A1 | Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy | THE REGENTS OF THE UNIVERSITY OF TEXAS | 2004-03-18 | — | — | US | disclosed |
| WO-2004020457-A2 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF DNA REPAIR PROTEIN XRCC-3 | CONNELL PHILIP (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1395255-A2 | CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1390075-A2 | CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY | The University of Chicago (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004007557-A2 | TF ANTAGONIST | NOVO NORDISK A/S (DK) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004005320-A2 | ErbB-2 RECEPTOR TARGETING PEPTIDE | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030232013-A1 | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2003-12-18 | — | — | US | disclosed |
| WO-2003097049-A1 | ANTI-ESTROGEN RECEPTOR AGENTS FOR CHEMOTHERAPY AND PREVENTION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-1355566-A2 | LOCAL REGIONAL CHEMOTHERAPY AND RADIOTHERAPY USING IN SITU HYDROGEL | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1355628-A2 | STABILISED POLYMERIC AEROSOLS FOR PULMONARY GENE DELIVERY | Board of Regents, The University of Texas System (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003072125-A1 | THERAPEUTIC AND DIAGNOSTIC TARGETING OF CANCERS CELLS WITH TUMOR HOMING PEPTIDES | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1328262-A2 | A METHOD TO INCORPORATE N-(4-HYDROXYPHENYL) RETINAMIDE IN LIPOSOMES | Board of Regents, The University of Texas System (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | VALLEY VENTURES III, L.P. | 2003-07-10 | — | — | US | disclosed |
| US-20030129262-A1 | Methionine restriction for cancer therapy | BAYLOR COLLEGE OF MEDICINE | 2003-07-10 | — | — | US | disclosed |
| US-20030125265-A1 | Anti-estrogen receptor agents for chemotherapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-07-03 | — | — | US | disclosed |
| EP-1322337-A2 | PEI : DNA VECTOR FORMULATIONS FOR IN VITRO AND IN VIVO GENE DELIVERY | Board of Regents, The University of Texas System (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030119732-A1 | CDDO-compounds and combination therapies thereof | BOARD OF | 2003-06-26 | — | — | US | disclosed |
| US-20030113897-A1 | Mutant p21Cip1/WAF1 and cell growth control and cell growth control | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-06-19 | — | — | US | disclosed |
| WO-2003045359-A2 | COMBINATION OF CIMETIDINE AND CYSTEINE DERIVATIVES FOR TREATING CANCER | ASTION ONCOLOGY APS (DK) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002041871-A9 | COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS | UNIV TEXAS (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030082685-A1 | Chemotherapeutic induction of egr-1 promoter activity | DANA-FARBER CANCER INSTITUTE | 2003-05-01 | — | — | US | disclosed |
| US-20030083261-A1 | Class of 12mer peptides that inhibit the function of the mitotic check point protein Mad2 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-05-01 | — | — | US | disclosed |
| EP-1297002-A2 | ISOLATION OF A CELL-SPECIFIC INTERNALIZING PEPTIDE THAT INFILTRATES TUMOR TISSUE FOR TARGETED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030053995-A1 | Methods and compositions for inhibiting EGF receptor activity | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-03-20 | — | — | US | disclosed |
| WO-2003020305-A1 | METHIONINE RESTRICTION FOR CANCER THERAPY | BAYLOR COLLEGE OF MEDECINE (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20030050236-A1 | Compounds that enhance tumor death | THE UNIVERSITY OF CHICAGO | 2003-03-13 | — | — | US | disclosed |
| EP-1290011-A1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | Oncopeptides AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002088327-A9 | METHODS FOR VIRAL ONCOAPOPTOSIS IN CANCER THERAPY | SINAI SCHOOL MEDICINE (US) | 2003-03-06 | — | — | WO | disclosed |
| US-6517828-B1 | C-CAM1 cytoplasmic domain; cellular adhesion molecule of carcinoembryonic antigen (CEA) gene family; expression construct comprising a nucleic acid sequence encoding SEQ ID NO:1 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-02-11 | — | — | US | disclosed |
| WO-2003006104-A2 | LYMPHATIC ENDOTHELIAL CELLS MATERIALS AND METHODS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20020187126-A1 | Methods for viral oncoapoptosis in cancer therapy | MOUNT SINAI SCHOOL OF MEDICINE | 2002-12-12 | — | — | US | disclosed |
| US-20020187105-A1 | Polymer combinations that result in stabilized aerosols for gene delivery to the lungs | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-12-12 | — | — | US | disclosed |
| EP-1259626-A2 | MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAS AND PROTEINS AND SCREENING METHODS FOR MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020169126-A1 | Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-11-14 | — | — | US | disclosed |
| WO-2002090519-A2 | MUTANT P21?CIP1/WAF1¿ AND CELL GROWTH CONTROL | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-11-14 | — | — | WO | disclosed |
| US-20020164667-A1 | VEGFR-3 inhibitor materials and methods | VEGENICS LIMITED (AU) | 2002-11-07 | — | — | US | disclosed |
| WO-2002080849-A2 | CHEMOTHERAPEUTIC INDUCTION OF EGR-1 PROMOTER ACTIVITY | UNIVERSITY OF CHICAGO (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020151680-A1 | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins | VEGENICS PTY LTD (AU) | 2002-10-17 | — | — | US | disclosed |
| US-20020151060-A1 | PEI: DNA vector formulations for in vitro and in vivo gene delivery | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-10-17 | — | — | US | disclosed |
| US-20020143062-A1 | Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-10-03 | — | — | US | disclosed |
| US-6444872-B1 | FUNGICIDE THERAPY CALIBRATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-09-03 | — | — | US | disclosed |
| WO-2002060412-A2 | STABILISED POLYMERIC AEROSOLS FOR PULMONARY GENE DELIVERY | BOARD OF REGENTS (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020102265-A1 | Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-08-01 | — | — | US | disclosed |
| WO-2002057299-A2 | VEGFR-3 BINDING PEPTIDES AND THEIR USE FOR INHIBITING ANGIOGENESIS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002049501-A2 | LOCAL REGIONAL CHEMOTHERAPY AND RADIOTHERAPY USING IN SITU HYDROGEL | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002047611-A2 | CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-06-20 | — | — | WO | disclosed |
| EP-1210433-A2 | METHODS AND COMPOSITIONS OF A NOVEL SERINE PROTEASE INHIBITOR | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2002041871-A2 | COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-05-30 | — | — | WO | disclosed |
| US-6395712-B1 | ANTITUMOR AGENTS; MIXTURE OF NUCLEIC ACID COMPLEX AND CISPLATIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-05-28 | — | — | US | disclosed |
| EP-1206178-A1 | A LARGE ANIMAL MODEL OF INVASIVE PULMONARY ASPERGILLOSIS IN AN IMMUNOCOMPROMISED HOST | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2002032413-A2 | A METHOD TO INCORPORATE N-(4-HYDROXYPHENYL) RETINAMIDE IN LIPOSOMES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002024232-A2 | PEI: DNA VECTOR FORMULATIONS FOR IN VITRO AND IN VIVO GENE DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1183273-A1 | C-CAM AS AN ANGIOGENESIS INHIBITOR | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1180016-A2 | METHODS AND COMPOSITIONS FOR NON-VIRAL GENE THERAPY FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | Introgen Therapeutics, Inc. (US) | 2002-02-20 | — | — | EP | disclosed |
| WO-2002002147-A2 | ISOLATION OF A CELL-SPECIFIC INTERNALIZING PEPTIDE THAT INFILTRATES TUMOR TISSUE FOR TARGETED DRUG DELIVERY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001096367-A1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | ONCOPEPTIDES AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001062942-A2 | MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6255347-B1 | ALZHEIMER'S DISEASE | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE | 2001-07-03 | — | — | US | disclosed |
| WO-2001016324-A2 | METHODS AND COMPOSITIONS OF A NOVEL SERINE PROTEASE INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2001011953-A1 | A LARGE ANIMAL MODEL OF INVASIVE PULMONARY ASPERGILLOSIS IN AN IMMUNOCOMPROMISED HOST | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000073340-A1 | C-CAM AS AN ANGIOGENESIS INHIBITOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000071096-A2 | METHODS AND COMPOSITIONS FOR NON-VIRAL GENE THERAPY FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | INTROGEN THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| US-6100254-A | Inhibitors of protein tyrosine kinases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-08-08 | — | — | US | disclosed |
| US-6090565-A | Sphingoglycolipids as markers for multidrug resistant cancers | JOHN WAYNE CANCER INSTITUTE (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000014234-A9 | PROSTATE SPECIFIC PROMOTER AND REGULATION OF GENE EXPRESSION | UROCOR INC (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000014234-A1 | PROSTATE SPECIFIC PROMOTER AND REGULATION OF GENE EXPRESSION | UROCOR, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| EP-0963440-A1 | IMPROVED METHODS FOR TRANSDUCING CELLS | Board of Regents, The University of Texas System (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999019306-A2 | 2,3-BENZODIAZEPIN-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF PROTEIN TYROSINE KINASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-04-22 | — | — | WO | disclosed |
| US-5885786-A | Methods for screening of substances for inhibition of multidrug resistance | JOHN WAYNE CANCER INSTITUTE (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0894139-A1 | SENSITIZATION OF HER-2/NEU OVEREXPRESSING CANCER CELLS TO CHEMOTHERAPY | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0877608-A1 | SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1998022605-A9 | IMPROVED METHODS FOR TRANSDUCING CELLS | — | 1998-10-15 | — | — | WO | disclosed |
| WO-1998022605-A1 | IMPROVED METHODS FOR TRANSDUCING CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1997048391-A9 | METHODS AND COMPOSITIONS COMPRISING R-IBUPROFEN | — | 1998-04-09 | — | — | WO | disclosed |
| WO-1997048391-A2 | METHODS AND COMPOSITIONS COMPRISING R-IBUPROFEN | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5695751-A | ADMINISTERING L-AMINO ACID OXIDASE TO REDUCE PLASMA LEVEL OF LARGE AMINO ACIDS TO ALLOW INCREASED TRANSPORT OF LARGE AMINO ACID DRUGS ACROSS BLOOD BRAIN BARRIER | CORNELL RESEARCH FOUNDATION, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1997040358-A1 | MARKERS FOR MULTIDRUG RESISTANT CANCERS | JOHN WAYNE CANCER INSTITUTE (US) | 1997-10-30 | — | — | WO | disclosed |
| WO-1997027848-A9 | SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS | — | 1997-10-16 | — | — | WO | disclosed |
| WO-1997035012-A1 | SENSITIZATION OF HER-2/NEU OVEREXPRESSING CANCER CELLS TO CHEMOTHERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-09-25 | — | — | WO | disclosed |
| WO-1997027848-A1 | SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-08-07 | — | — | WO | disclosed |
| EP-0604301-B1 | p-Di[2-chloroethyl)amino]phenylalanine derivatives process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-05-29 | — | — | EP | disclosed |
| EP-0604301-B1 | p-Di[2-chloroethyl)amino]phenylalanine derivatives process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-05-29 | — | — | EP | disclosed |
| EP-0450480-B1 | Somatostatin Analogues | UNIV TULANE (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5424464-A | Used for treating leukemia | ADIR ET COMPAGNIE (FR) | 1995-06-13 | — | — | US | disclosed |
| US-5424464-A | Used for treating leukemia | ADIR ET COMPAGNIE (FR) | 1995-06-13 | — | — | US | disclosed |
| EP-0604301-A1 | p-Di[2-chloroethyl)amino]phenylalanine derivatives process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604301-A1 | p-Di[2-chloroethyl)amino]phenylalanine derivatives process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-06-29 | — | — | EP | disclosed |
| EP-0450480-A2 | Somatostatin Analogues | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0233733-A2 | Process for producing N-phthaloyl-p-nitro-L-phenylalanine | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-08-26 | — | — | EP | disclosed |
| CN-86106232-A | Insulation adhesive band composition and complex thereof | — | 1987-06-03 | — | — | CN | disclosed |
| US-4181669-A | A CARBODIIMIDE WITH ACID CATALYSTS AS A CONDENSATION AGENT | AKTIEBOLAGET LEO (SE) | 1980-01-01 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896668-B2 | Lyophilized preparation of cytotoxic dipeptides | TREH, SORD, SI | HIF1A 633/4885CYP3A4 3189/4885ALDH1A1 3421/4885 |
| US-20140378673-A1 | PRODRUG USING NITROIMIDAZOLE | HIF1AN, HIF1A, PAICS | HIF1A 2/4885CYP3A4 230/4885ALDH1A1 133/4885 |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | HIF1A 722/4885CYP3A4 2764/4885ALDH1A1 730/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | HIF1A 2628/4885CYP3A4 3207/4885ALDH1A1 1779/4885 |
| US-20140128462-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | TREH, SORD, SI | HIF1A 633/4885CYP3A4 3189/4885ALDH1A1 3421/4885 |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | PIK3CA, PIK3CD, MCL1 | HIF1A 2296/4885CYP3A4 2748/4885ALDH1A1 2747/4885 |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | HIF1A 3779/4885CYP3A4 385/4885ALDH1A1 2851/4885 |
| US-10940128-B2 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same | MCL1, MYADM, IL2 | HIF1A 2469/4885CYP3A4 2708/4885ALDH1A1 3835/4885 |
| US-20170137431-A1 | MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME | CBR1, CNR1, CNR2 | HIF1A 2983/4885CYP3A4 1348/4885ALDH1A1 466/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | HIF1A 1824/4885CYP3A4 403/4885ALDH1A1 2240/4885 |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | DSG1, DEGS1, PLA2G2E | HIF1A 3779/4885CYP3A4 385/4885ALDH1A1 2851/4885 |
| US-20240216529-A1 | EXTRACELLULAR VESICLES WITH TARGETING MOIETY | EXOSC5, EXOSC4, EXOSC10 | HIF1A 555/4885CYP3A4 4879/4885ALDH1A1 3325/4885 |
| US-20260053737-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | ARG1, ARG2, PDE6D | HIF1A 948/4885CYP3A4 4158/4885ALDH1A1 4119/4885 |
| US-11660266-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | PDE6C, CHMP4B, PDE6D | HIF1A 973/4885CYP3A4 3771/4885ALDH1A1 2765/4885 |
| US-20210155903-A1 | Combination Therapy | ICOS, CD274, PDCD1LG2 | HIF1A 1498/4885CYP3A4 3110/4885ALDH1A1 1948/4885 |
| US-20190240332-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | TREH, SORD, SI | HIF1A 633/4885CYP3A4 3189/4885ALDH1A1 3421/4885 |
| US-20040097421-A1 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | MCL1, LNPEP, MYADM | HIF1A 693/4885CYP3A4 4312/4885ALDH1A1 3638/4885 |
| US-20250042963-A1 | METHODS FOR TREATING MYELOPROLIFERATIVE DISORDERS | MPL, JAK2, PTPRJ | HIF1A 1587/4885CYP3A4 4752/4885ALDH1A1 2392/4885 |
| US-20090240074-A1 | Process Of Making Optically Pure Melphalan | TYR, PAH, TET2 | HIF1A 261/4885CYP3A4 121/4885ALDH1A1 717/4885 |
| US-20140312218-A1 | COVALENTLY FUNCTIONALIZED NANODIAMOND-BASED MALDI MATRICES AND METHODS OF USE THEREOF | ITGA2B, MMP2, ITGAV | HIF1A 1248/4885CYP3A4 3354/4885ALDH1A1 1988/4885 |
| US-20040266834-A1 | Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy | PPARD, PPARG, NCOA4 | HIF1A 1430/4885CYP3A4 2712/4885ALDH1A1 277/4885 |
| US-20220332778-A1 | METHODS FOR TREATING MYELOPROLIFERATIVE DISORDERS | MPL, JAK2, PTPRJ | HIF1A 1587/4885CYP3A4 4752/4885ALDH1A1 2392/4885 |
| US-20200345848-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | TREH, SORD, SI | HIF1A 469/4885CYP3A4 3234/4885ALDH1A1 3545/4885 |
| US-20100311838-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | MCL1, MYADM, IL2 | HIF1A 2469/4885CYP3A4 2708/4885ALDH1A1 3835/4885 |
| US-12357564-B2 | Methods and compositions for sustained release microparticles for ocular drug delivery | PDE6C, CHMP4B, PDE6D | HIF1A 973/4885CYP3A4 3771/4885ALDH1A1 2765/4885 |
| US-20120190887-A1 | Processes for preparing pharmaceutical grade melphalans from industrial grade reactants | TYR, MITF, ENY2 | HIF1A 587/4885CYP3A4 1668/4885ALDH1A1 3806/4885 |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | CTSL, DNPEP, CTSE | HIF1A 3644/4885CYP3A4 1298/4885ALDH1A1 2008/4885 |
| US-20170049894-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | TREH, SORD, SI | HIF1A 633/4885CYP3A4 3189/4885ALDH1A1 3421/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | HIF1A 1288/4885CYP3A4 70/4885ALDH1A1 265/4885 |
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | RECQL, DDX21, DDX41 | HIF1A 3374/4885CYP3A4 4214/4885ALDH1A1 3786/4885 |
| US-20220323585-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | TREH, SORD, SI | HIF1A 633/4885CYP3A4 3189/4885ALDH1A1 3421/4885 |
| US-20150080632-A1 | MARINOPYRROLE DERIVATIVES AS ANTICANCER AGENTS | MAP2, MAP4, MDN1 | HIF1A 4492/4885CYP3A4 961/4885ALDH1A1 1771/4885 |
| US-20140221488-A1 | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | MCL1, MYADM, IL2 | HIF1A 2469/4885CYP3A4 2708/4885ALDH1A1 3835/4885 |
| US-20260108480-A1 | METHODS FOR INDUCING PROLIFERATION OF STEM CELLS | CYP4X1, SLC6A7, ZFX | HIF1A 3560/4885CYP3A4 1047/4885ALDH1A1 503/4885 |
| US-10322182-B2 | Lyophilized preparation of cytotoxic dipeptides | TREH, SORD, SI | HIF1A 633/4885CYP3A4 3189/4885ALDH1A1 3421/4885 |
| US-20040072755-A1 | TF antagonist | TFPI, TFPI2, F3 | HIF1A 682/4885CYP3A4 2851/4885ALDH1A1 4849/4885 |
| US-20160016889-A1 | An Improved Process for the Synthesis of Melphalan and the Hydrochloride Salt | MCL1, DCPS, MEN1 | HIF1A 1593/4885CYP3A4 2944/4885ALDH1A1 3392/4885 |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | HIF1A 3779/4885CYP3A4 385/4885ALDH1A1 2851/4885 |
| US-20250092083-A1 | STEROL BASED IONIZABLE LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME | NPC1L1, NPC1, SREBF1 | HIF1A 985/4885CYP3A4 3146/4885ALDH1A1 3025/4885 |
| US-20230398063-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | PDE6C, CHMP4B, PDE6D | HIF1A 973/4885CYP3A4 3771/4885ALDH1A1 2765/4885 |
| US-20200121794-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | TREH, SORD, SI | HIF1A 633/4885CYP3A4 3189/4885ALDH1A1 3421/4885 |
| US-20090093447-A1 | CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF | CD74, BAD, PDCD4 | HIF1A 2182/4885CYP3A4 1023/4885ALDH1A1 181/4885 |
| US-10682371-B2 | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof | MET, ARG1, CD4 | HIF1A 70/4885CYP3A4 742/4885ALDH1A1 3371/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | HIF1A 568/4885CYP3A4 1342/4885ALDH1A1 785/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | HIF1A 722/4885CYP3A4 2764/4885ALDH1A1 730/4885 |
| US-20160090352-A1 | PROCESS FOR THE PURIFICATION OF MELPHALAN | MYADM, MANBA, PTMA | HIF1A 1379/4885CYP3A4 3173/4885ALDH1A1 3594/4885 |
| US-20120065230-A1 | Nitroxide Free Radical Synergized Antineoplastic Agents | NOX1, NQO1, TXNRD2 | HIF1A 845/4885CYP3A4 289/4885ALDH1A1 306/4885 |
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | CBR3, GRHPR, CTH | HIF1A 1283/4885CYP3A4 205/4885ALDH1A1 1092/4885 |
| US-20230382819-A1 | PROCESSES FOR SYNTHESIS OF ALPHA-EMITTING RADIOPHARMACEUTICALS | POLQ, HBZ, GAA | HIF1A 235/4885CYP3A4 1793/4885ALDH1A1 2554/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | HIF1A 2356/4885CYP3A4 64/4885ALDH1A1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.